Skip to main content
    A

    Abbott Laboratories (ABT)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $107.52
    -1.00 (-0.92%)

    Market Cap: $187.95B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Abbott Laboratories (ABT) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Abbott Laboratories (ABT) trades at 20.0x trailing earnings and 3.9x sales. Its P/E of 20.0x is below its 5-year median of 23.7x. Its forward P/E is 18.3x. The median P/E across 10 similar companies is 19.0x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 9.3% higher over the next year. Its free cash flow yield is 3.6%.

    MultipleValue
    P/E (trailing)20.0x
    Forward P/E18.3x
    Price to sales3.9x
    Price to book3.7x
    EV/EBITDA19.1x
    Price to FCF27.6x
    EV/FCF31.6x
    PEG1.6
    FCF yield3.6%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 17.7% below 24.3x, its P/S is 15.2% below 4.6x and its P/B is 21.3% below 4.7x.

    MultipleCurrent5-year median10-year median
    P/E20.0x23.7x24.3x
    P/S3.9x4.6x4.6x
    P/B3.7x4.8x4.7x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 17.5x in 2016 to 30.0x in 2020.

    Year endPriceP/EP/SP/B
    2025$125.2924.3x4.9x4.2x
    2024$113.1124.2x4.7x4.1x
    2023$110.0724.8x4.8x5.0x
    2022$109.7920.6x4.4x5.2x
    2021$140.7427.0x5.8x7.0x
    2020$109.4930.0x5.6x6.0x
    2019$86.8626.8x4.8x5.0x
    2018$72.3325.1x4.2x4.2x
    2017$57.0722.8x3.6x3.2x
    2016$38.4117.5x2.7x2.8x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About ABT

    What is ABT's forward P/E ratio?

    Abbott Laboratories has a forward P/E ratio of 18.3x.

    Is ABT stock overvalued?

    GNG's valuation label for ABT is Undervalued. Its P/E of 20.0x compares with a median of 19.0x across 10 similar companies.

    What is ABT's price to sales ratio?

    Abbott Laboratories has a price to sales ratio of 3.9x.

    What is Abbott Laboratories's average P/E ratio over 5 years?

    Abbott Laboratories's median P/E over the last 5 years is 23.7x, from 60 month-end values through Oct 2026.

    What is ABT's PEG ratio?

    Abbott Laboratories has a PEG ratio of 1.6.